Lineage Cell Therapeutics Poised for $20B Cell Therapy Market Expansion
Lineage Cell Therapeutics is cited among leading biotech companies in the global cell therapy market, valued at $4.7 billion in 2023 and expected to top $20 billion by 2030. Broader senolytic and neurodegenerative treatment markets could reach $6.39 billion and $85 billion by 2032, highlighting strong sector growth.
1. Market Outlook
The global cell therapy market was valued at $4.7 billion in 2023 and is projected to exceed $20 billion by 2030 as more therapies advance toward commercialization. The senolytic and anti-aging pharmaceuticals sector could reach $6.39 billion by 2030, while the neurodegenerative treatment market is forecast to grow from $58.4 billion in 2025 to $85 billion by 2032.
2. Lineage Cell Therapeutics Positioning
Lineage Cell Therapeutics is among the companies developing regenerative neural therapies aimed at repairing damaged neurons, reducing brain inflammation and slowing disease progression. Its participation in these high-growth markets positions the company to benefit from rising institutional investment and expanding clinical pipelines in both anti-aging and neurological disease therapies.